Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
TECH

TECH - Bio-Techne Corp Stock Price, Fair Value and News

75.45USD-0.47 (-0.62%)Market Closed

Market Summary

TECH
USD75.45-0.47
Market Closed
-0.62%

TECH Stock Price

View Fullscreen

TECH RSI Chart

TECH Valuation

Market Cap

11.9B

Price/Earnings (Trailing)

58.6

Price/Sales (Trailing)

10.3

EV/EBITDA

33.63

Price/Free Cashflow

47.34

TECH Price/Sales (Trailing)

TECH Profitability

EBT Margin

20.13%

Return on Equity

10.07%

Return on Assets

7.46%

Free Cashflow Yield

2.11%

TECH Fundamentals

TECH Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

3.16%

Rev. Growth (Qtr)

11.31%

TECH Earnings

Earnings (TTM)

202.9M

Earnings Growth (Yr)

-30.13%

Earnings Growth (Qtr)

78.62%

Breaking Down TECH Revenue

Last 7 days

-2.4%

Last 30 days

1.2%

Last 90 days

21.5%

Trailing 12 Months

-13.2%

How does TECH drawdown profile look like?

TECH Financial Health

Current Ratio

4.08

Debt/Equity

0.19

Debt/Cashflow

0.79

TECH Investor Care

Dividend Yield

0.42%

Dividend/Share (TTM)

0.32

Shares Dilution (1Y)

0.09%

Diluted EPS (TTM)

1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.2B000
20231.1B1.1B1.1B1.1B
20221.1B1.1B1.1B1.1B
2021847.8M931.0M984.6M1.0B
2020754.5M738.7M759.6M799.0M
2019702.6M714.0M734.3M744.7M
2018619.3M643.0M661.4M681.7M
2017541.2M563.0M577.0M599.4M
2016481.9M499.0M517.2M528.1M
2015434.3M452.2M456.1M465.1M
2014344.7M357.8M380.6M398.5M
2013309.8M310.6M321.2M330.2M
2012313.9M314.6M312.0M312.4M
2011278.6M290.0M299.6M306.6M
2010267.8M269.0M270.5M272.6M
20090264.0M265.2M266.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bio-Techne Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 08, 2024
higgins john l
acquired
137,700
22.95
6,000
-
May 14, 2024
higgins john l
sold
-335,377
83.8443
-4,000
-
May 14, 2024
higgins john l
acquired
91,800
22.95
4,000
-
May 01, 2024
klimovsky judith v
acquired
-
-
680
-
Apr 03, 2024
bohnen shane
acquired
-
-
2,259
svp - general counsel
Apr 03, 2024
bohnen shane
sold (taxes)
-50,698
67.87
-747
svp - general counsel
Mar 07, 2024
nusse roeland
sold
-800,627
76.9834
-10,400
-
Feb 01, 2024
geist william
sold (taxes)
-76,147
68.54
-1,111
president, protein sciences

1–10 of 50

Which funds bought or sold TECH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
HARBOR INVESTMENT ADVISORY, LLC
added
4.06
7,086
126,749
0.01%
Jul 19, 2024
OFI INVEST ASSET MANAGEMENT
new
-
1,036,230
1,036,230
0.03%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
reduced
-1.98
-10,818
4,788,510
0.03%
Jul 19, 2024
Oakworth Capital, Inc.
unchanged
-
111
6,305
-%
Jul 19, 2024
PARSONS CAPITAL MANAGEMENT INC/RI
unchanged
-
8,633
490,946
0.03%
Jul 19, 2024
Johnson & White Wealth Management, LLC
unchanged
-
4,000
244,000
0.23%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
added
1.17
18,809
649,292
-%
Jul 19, 2024
Values First Advisors, Inc.
added
30.65
513,604
2,070,550
1.24%
Jul 19, 2024
FIRST CITIZENS BANK & TRUST CO
reduced
-22.01
-94,470
363,838
0.01%
Jul 19, 2024
Accredited Investors Inc.
reduced
-17.05
-57,584
312,383
0.02%

1–10 of 50

Are Funds Buying or Selling TECH?

Are funds buying TECH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TECH
No. of Funds

Unveiling Bio-Techne Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.53%
18,228,210
SC 13G/A
Jan 24, 2024
blackrock inc.
11.5%
18,133,912
SC 13G/A
Feb 09, 2023
vanguard group inc
11.59%
18,199,432
SC 13G/A
Jan 26, 2023
blackrock inc.
10.1%
15,888,640
SC 13G/A
Jan 20, 2023
blackrock inc.
10.1%
15,888,640
SC 13G
Feb 09, 2022
vanguard group inc
11.27%
4,426,638
SC 13G/A
Jan 27, 2022
blackrock inc.
11.0%
4,328,299
SC 13G/A
Jan 25, 2022
blackrock inc.
11.0%
4,328,299
SC 13G/A
Sep 10, 2021
vanguard group inc
11.04%
4,315,543
SC 13G/A
Feb 10, 2021
vanguard group inc
9.30%
3,591,352
SC 13G/A

Recent SEC filings of Bio-Techne Corp

View All Filings
Date Filed Form Type Document
Jul 10, 2024
4
Insider Trading
May 31, 2024
SD
SD
May 16, 2024
4
Insider Trading
May 14, 2024
144
Notice of Insider Sale Intent
May 06, 2024
10-Q
Quarterly Report
May 03, 2024
4
Insider Trading
May 03, 2024
3
Insider Trading
May 01, 2024
8-K
Current Report
Apr 30, 2024
8-K
Current Report

Peers (Alternatives to Bio-Techne Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Bio-Techne Corp News

Latest updates
Defense World11 hours ago
American Banking and Market News17 Jul 202410:18 am
Yahoo Finance23 May 202407:00 am

Bio-Techne Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue11.3%303273277301294272270288290269258259244224204176195185183192185
Gross Profit15.9%205177185205202183180200201184171176168151138113130121118128125
Operating Expenses-0.7%13813912911012211512312011112110810710010089.0074.0082.0084.0085.0085.0081.00
  S&GA Expenses-3.3%11211610587.0099.0093.0099.0097.0089.0010186.0087.0083.0083.0073.0057.0066.0068.0069.0069.0065.00
EBITDA Margin-5.0%0.31*0.33*0.36*0.40*0.40*0.39*0.40*0.37*0.32*0.30*0.28*0.27*---------
Interest Expenses-1.8%4.004.005.005.001.002.003.003.002.003.003.003.003.004.004.005.004.005.005.005.00-2.52
Income Taxes103.1%12.006.00-1.4313.0010.0016.0014.0017.009.0014.00-1.60-7.53-0.0510.006.003.0010.0031.003.006.005.00
Earnings Before Taxes83.0%61.0033.0050.0088.0080.0066.0010479.0069.0086.0067.007.0045.0056.0039.0062.0047.0015018.0023.0050.00
EBT Margin-8.3%0.20*0.22*0.25*0.30*0.29*0.28*0.30*0.27*0.21*0.20*0.18*0.16*---------
Net Income78.6%49.0027.0051.0075.0070.0050.0090.0066.0061.0072.0069.0015.0046.0046.0033.0059.0036.0012014.0016.0045.00
Net Income Margin-10.2%0.18*0.20*0.22*0.25*0.25*0.24*0.26*0.24*0.20*0.20*0.18*0.15*---------
Free Cashflow-5.4%65.0068.0046.0073.0039.0058.0047.0089.0058.0091.0042.00111---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.4%2,7212,7312,7552,6392,6002,3632,3512,2952,3002,3052,2702,2632,0852,0682,0532,0281,9991,9981,9251,8841,873
  Current Assets3.4%611591591621571565552606593590544511567542542521492465392413423
    Cash Equivalents7.5%14013014918112716516517316121219619918616616914715611010010196.00
  Inventory-0.7%17918118617216916015014112812211711711010710610310095.0091.0091.0094.00
  Net PPE4.1%244234232226224224224223218212207208199196192177165164157154145
  Goodwill-0.9%97198096987387187086582282883284384395.00728732728726734730733720
  Current Liabilities10.8%15013512812914112813817616715513415213811810510710510588.0010298.00
  Long Term Debt-13.0%389447440350370200265243247270288329203219311344407370474493510
    LT Debt, Current--------13.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.00
Shareholder's Equity2.6%2,0141,9641,9981,96710.0012.0013.008.001,7131,7031,6471,5711,5481,5311,4391,3811,2911,3231,1741,1661,146
  Retained Earnings2.9%1,2981,2611,3281,3091,2471,2001,1631,1231,1331,1461,1191,0851,0891,1051,0731,0571,0131,039931932928
  Additional Paid-In Capital3.4%790764747722715701680652636616584534514481449421382363334317298
Accumulated Depreciation-252--234-----------------
Shares Outstanding0.3%158157158158157157157157157157156155---------
Minority Interest---------0.76-1.05-0.468.008.008.009.00-------
Float------13,000---20,300---12,400---8,400---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-2.6%81.0083.0059.0083.0051.0064.0056.0010373.0010148.0012275.0089.0066.0045.0049.0070.0041.0056.0040.00
  Share Based Compensation-36.2%8.0013.0010.00-2.0810.0017.0014.008.008.0014.0012.0010.0011.0016.0013.006.008.0010.008.008.006.00
Cashflow From Investing30.5%-16.44-23.67-154-4.76-241-0.11-19.69-18.57-35.99-35.17-7.12-2260.00-8.60-8.14-10.4719.0033.00-15.08-30.32-4.74
Cashflow From Financing35.6%-52.42-81.4072.00-24.22151-72.19-31.81-65.73-84.06-53.38-39.68118-55.23-90.08-34.93-44.72-17.79-97.03-24.27-19.90-27.04
  Dividend Payments0.2%13.0013.0013.0013.0013.0013.0013.0013.0013.0013.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.00
  Buy Backs-------20.0059.0061.00---43.00---50.00---0.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TECH Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME    
Net sales$ 303,428$ 294,146$ 852,961$ 835,382
Cost of sales98,82991,984286,584270,265
Gross margin204,599202,162566,377565,117
Operating expenses:    
Selling, general and administrative111,84099,238332,839291,624
Research and development25,76122,71372,67569,074
Total operating expenses137,601121,951405,514360,698
Operating income66,99880,211160,863204,419
Other income (expense)(5,914)(15)(16,835)45,924
Earnings before income taxes61,08480,196144,028250,343
Income taxes12,0259,97816,51140,385
Net earnings, including noncontrolling interest49,05970,218127,517209,958
Net earnings attributable to noncontrolling interest000179
Net earnings attributable to Bio-Techne49,05970,218127,517209,779
Other comprehensive income (loss):    
Foreign currency translation income (loss)(11,981)3,282(5,558)(805)
Foreign currency translation reclassified to earnings with Eminence deconsolidation000119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8335(1,708)(3,685)2,302
Other comprehensive income (loss)(11,646)1,574(9,243)1,616
Other comprehensive income (loss) attributable to noncontrolling interest000(33)
Other comprehensive income (loss) attributable to Bio-Techne(11,646)1,574(9,243)1,649
Comprehensive income attributable to Bio-Techne$ 37,413$ 71,792$ 118,274$ 211,428
Earnings per share attributable to Bio-Techne:    
Basic (in dollars per share)$ 0.31$ 0.45$ 0.81$ 1.34
Diluted (in dollars per share)$ 0.31$ 0.43$ 0.79$ 1.30
Weighted average common shares outstanding:    
Basic (in shares)157,309157,311157,655157,071
Diluted (in shares)160,496161,615160,817161,768

TECH Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 139,915$ 180,571
Short-term available-for-sale investments5,39723,739
Accounts receivable, less allowance for doubtful accounts of $3,293 and $4,738, respectively227,887218,468
Inventories179,496171,638
Current assets held-for-sale26,6690
Other current assets31,28627,066
Total current assets610,650621,482
Property and equipment, net243,728226,200
Right-of-use assets97,25898,326
Goodwill970,966872,737
Intangible assets, net526,428534,645
Other assets272,140285,302
Total assets2,721,1702,638,692
Current liabilities:  
Trade accounts payable28,89525,679
Salaries, wages and related accruals44,31336,747
Accrued expenses17,80614,880
Contract liabilities30,10823,069
Income taxes payable12,08212,022
Operating lease liabilities - current12,97811,199
Contingent consideration payable03,500
Current liabilities held-for-sale6890
Other current liabilities2,9491,413
Total current liabilities149,820128,509
Deferred income taxes63,66688,982
Long-term debt obligations389,000350,000
Operating lease liabilities92,75293,766
Other long-term liabilities11,55710,919
Bio-Techne's Shareholders' equity:  
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding00
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,554,366 and 157,641,914 respectively1,5761,576
Additional paid-in capital790,418721,543
Retained earnings1,297,6881,309,461
Accumulated other comprehensive loss(75,307)(66,064)
Total Bio-Techne's shareholders' equity2,014,3751,966,516
Total liabilities and shareholders' equity$ 2,721,170$ 2,638,692
TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEbio-techne.com
 INDUSTRYBiotechnology
 EMPLOYEES3050

Bio-Techne Corp Frequently Asked Questions


What is the ticker symbol for Bio-Techne Corp? What does TECH stand for in stocks?

TECH is the stock ticker symbol of Bio-Techne Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Techne Corp (TECH)?

As of Fri Jul 19 2024, market cap of Bio-Techne Corp is 11.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers. The fair value of Bio-Techne Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Techne Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TECH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Techne Corp a good stock to buy?

The fair value guage provides a quick view whether TECH is over valued or under valued. Whether Bio-Techne Corp is cheap or expensive depends on the assumptions which impact Bio-Techne Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TECH.

What is Bio-Techne Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, TECH's PE ratio (Price to Earnings) is 58.6 and Price to Sales (PS) ratio is 10.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TECH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Techne Corp's stock?

In the past 10 years, Bio-Techne Corp has provided 0.135 (multiply by 100 for percentage) rate of return.